{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:10:20Z","timestamp":1794237020927,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current therapeutic options for intrahepatic cholangiocarcinoma (ICC) are very limited, which is largely attributed to poor understanding of molecular pathogenesis of ICC. Breast cancer type 1 susceptibility protein-associated protein-1 (BAP1) has been reported to be a broad-spectrum tumor suppressor in many tumor types, yet its role in ICC remains unknown. The aim of this study was to investigate the clinical implications and biological function of BAP1 in ICC. Our results showed that the messenger RNA and protein levels of BAP1 were significantly downregulated in ICC versus paired non-tumor tissues. Overexpression of wild-type but not mutant BAP1 significantly suppressed ICC cell proliferation, cell cycle progression, and invasion in vitro, as well as tumor progression in vivo. Conversely, knockdown of BAP1 yielded opposing effects. Mechanistically, BAP1 functioned as a tumor suppressor in ICC by inhibiting the extracellular signal-regulated kinase 1\/2 and c-Jun N-terminal kinase\/c-Jun pathways, and this function was abolished by inactivating mutations. Clinically, low BAP1 expression was positively correlated with aggressive tumor characteristics, such as larger tumor size, presence of lymphatic metastasis, and advanced tumor node metastasis stage. Survival analysis revealed that low BAP1 expression was significantly and independently associated with poor overall survival and relapse-free survival after curative surgery. In conclusion, BAP1 is a putative tumor suppressor of ICC, and may serve as a valuable prognostic biomarker as well as potential therapeutic target for ICC.<\/jats:p>","DOI":"10.1038\/s41419-018-1087-7","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T15:50:43Z","timestamp":1539186643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways"],"prefix":"10.1038","volume":"9","author":[{"given":"Xu-Xiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Jian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"1087_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/hep.26958","volume":"60","author":"B Njei","year":"2014","unstructured":"Njei, B. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma. Hepatology 60, 1107\u20131108 (2014).","journal-title":"Hepatology"},{"key":"1087_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21037\/hbsn.2017.01.02","volume":"6","author":"A Gupta","year":"2017","unstructured":"Gupta, A. & Dixon, E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg. Nutr. 6, 101\u2013104 (2017).","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2","key":"1087_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"Sumera Rizvi","year":"2017","unstructured":"Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95\u2013111 (2018).","journal-title":"Nature Reviews Clinical Oncology"},{"key":"1087_CR4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet 383, 2168\u20132179 (2014).","journal-title":"Lancet"},{"key":"1087_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Yang, T., Wu, M. & Shen, F. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 379, 198\u2013205 (2016).","journal-title":"Cancer Lett."},{"key":"1087_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60, 1268\u20131289 (2014).","journal-title":"J. Hepatol."},{"key":"1087_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero, D. et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch. Surg. 147, 1107\u20131113 (2012).","journal-title":"Arch. Surg."},{"key":"1087_CR8","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1038\/onc.2012.617","volume":"32","author":"D Sia","year":"2013","unstructured":"Sia, D., Tovar, V., Moeini, A. & Llovet, J. M. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 32, 4861\u20134870 (2013).","journal-title":"Oncogene"},{"key":"1087_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","volume":"67","author":"S Rizvi","year":"2017","unstructured":"Rizvi, S. & Gores, G. J. Emerging molecular therapeutic targets for cholangiocarcinoma. J. Hepatol. 67, 632\u2013644 (2017).","journal-title":"J. Hepatol."},{"key":"1087_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","volume":"22","author":"A Moeini","year":"2016","unstructured":"Moeini, A., Sia, D., Bardeesy, N., Mazzaferro, V. & Llovet, J. M. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin. Cancer Res. 22, 291\u2013300 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1087_CR11","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/ERC-14-0005","volume":"22","author":"DE Johnson","year":"2015","unstructured":"Johnson, D. E. The ubiquitin\u2013proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr. Relat. Cancer 22, T1\u2013T17 (2015).","journal-title":"Endocr. Relat. Cancer"},{"key":"1087_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2015.03.032","volume":"362","author":"I Tiwari","year":"2015","unstructured":"Tiwari, I., Yoon, M. H., Park, B. J. & Jang, K. L. Hepatitis C virus core protein induces epithelial\u2013mesenchymal transition in human hepatocytes by upregulating E12\/E47 levels. Cancer Lett. 362, 131\u2013138 (2015).","journal-title":"Cancer Lett."},{"key":"1087_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153\u2013159 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1087_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10555-017-9705-x","volume":"36","author":"CL Soave","year":"2017","unstructured":"Soave, C. L., Guerin, T., Liu, J. & Dou, Q. P. Targeting the ubiquitin\u2013proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastas. Rev. 36, 717\u2013736 (2017).","journal-title":"Cancer Metastas. Rev."},{"key":"1087_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan, J. A., Jacq, X., Martin, N. M. & Jackson, S. P. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 17, 57\u201378 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1087_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fgene.2016.00133","volume":"7","author":"A Pinto-Fernandez","year":"2016","unstructured":"Pinto-Fernandez, A. & Kessler, B. M. DUBbing cancer: deubiquitylating enzymes involved in epigenetics, DNA damage and the cell cycle as therapeutic targets. Front. Genet. 7, 133 (2016).","journal-title":"Front. Genet."},{"key":"1087_CR17","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097\u20131112 (1998).","journal-title":"Oncogene"},{"key":"1087_CR18","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","volume":"74","author":"IH Ismail","year":"2014","unstructured":"Ismail, I. H. et al. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 74, 4282\u20134294 (2014).","journal-title":"Cancer Res."},{"key":"1087_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","volume":"60","author":"ZM Eletr","year":"2011","unstructured":"Eletr, Z. M. & Wilkinson, K. D. An emerging model for BAP1\u2019s role in regulating cell cycle progression. Cell Biochem. Biophys. 60, 3\u201311 (2011).","journal-title":"Cell Biochem. Biophys."},{"key":"1087_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","volume":"45","author":"R Murali","year":"2013","unstructured":"Murali, R., Wiesner, T. & Scolyer, R. A. Tumours associated with BAP1 mutations. Pathology 45, 116\u2013126 (2013).","journal-title":"Pathology"},{"key":"1087_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/gcc.22381","volume":"55","author":"C Luchini","year":"2016","unstructured":"Luchini, C. et al. Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis. Genes Chromosomes Cancer 55, 741\u2013749 (2016).","journal-title":"Genes Chromosomes Cancer"},{"key":"1087_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4137\/CMO.S15239","volume":"8","author":"A Battaglia","year":"2014","unstructured":"Battaglia, A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin. Med. Insights Oncol. 8, 37\u201347 (2014).","journal-title":"Clin. Med. Insights Oncol."},{"key":"1087_CR23","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410\u20131413 (2010).","journal-title":"Science"},{"key":"1087_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cge.12501","volume":"88","author":"KA Wadt","year":"2015","unstructured":"Wadt, K. A. et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin. Genet. 88, 267\u2013272 (2015).","journal-title":"Clin. Genet."},{"key":"1087_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10689-005-2833-4","volume":"4","author":"I Coupier","year":"2005","unstructured":"Coupier, I. et al. BAP1 and breast cancer risk. Fam. Cancer 4, 273\u2013277 (2005).","journal-title":"Fam. Cancer"},{"key":"1087_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pena-Llopis","year":"2012","unstructured":"Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751\u2013759 (2012).","journal-title":"Nat. Genet."},{"key":"1087_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet."},{"key":"1087_CR28","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya, Y. et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836\u20132844 (2016).","journal-title":"Cancer Res."},{"key":"1087_CR29","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","volume":"45","author":"Y Jiao","year":"2013","unstructured":"Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470\u20131473 (2013).","journal-title":"Nat. Genet."},{"key":"1087_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474\u20131478 (2013).","journal-title":"Nat. Genet."},{"key":"1087_CR31","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/cncr.25712","volume":"117","author":"O Farges","year":"2011","unstructured":"Farges, O. et al. AJCC7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 117, 2170\u20132177 (2011).","journal-title":"Cancer"},{"key":"1087_CR32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar, A. A. & Poulikakos, P. I. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 13, 928\u2013942 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1087_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bph.12432","volume":"171","author":"C Bubici","year":"2014","unstructured":"Bubici, C. & Papa, S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br. J. Pharmacol. 171, 24\u201337 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"1087_CR34","first-page":"1","volume":"1806","author":"Y Fang","year":"2010","unstructured":"Fang, Y., Fu, D. & Shen, X. Z. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim. Biophys. Acta 1806, 1\u20136 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"1087_CR35","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/bjc.2014.417","volume":"111","author":"H Kalirai","year":"2014","unstructured":"Kalirai, H., Dodson, A., Faqir, S., Damato, B. E. & Coupland, S. E. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br. J. Cancer 111, 1373\u20131380 (2014).","journal-title":"Br. J. Cancer"},{"key":"1087_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.juro.2013.09.041","volume":"191","author":"P Kapur","year":"2014","unstructured":"Kapur, P. et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J. Urol. 191, 603\u2013610 (2014).","journal-title":"J. Urol."},{"key":"1087_CR37","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1007\/s13277-015-3983-0","volume":"37","author":"S Yan","year":"2016","unstructured":"Yan, S. et al. Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. Tumour Biol. 37, 6125\u20136133 (2016).","journal-title":"Tumour Biol."},{"key":"1087_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0541-8","volume":"30","author":"J Tang","year":"2013","unstructured":"Tang, J. et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med. Oncol. 30, 541 (2013).","journal-title":"Med. Oncol."},{"key":"1087_CR39","doi-asserted-by":"publisher","first-page":"E182","DOI":"10.25011\/cim.v35i4.17146","volume":"35","author":"LH Fan","year":"2012","unstructured":"Fan, L. H. et al. BAP1 is a good prognostic factor in advanced non-small cell lung cancer. Clin. Invest. Med. 35, E182\u2013E189 (2012).","journal-title":"Clin. Invest. Med."},{"key":"1087_CR40","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","volume":"68","author":"KH Ventii","year":"2008","unstructured":"Ventii, K. H. et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 68, 6953\u20136962 (2008).","journal-title":"Cancer Res."},{"key":"1087_CR41","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1128\/MCB.01517-08","volume":"29","author":"S Misaghi","year":"2009","unstructured":"Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol. Cell. Biol. 29, 2181\u20132192 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"1087_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4110\/in.2016.16.2.85","volume":"16","author":"HB Low","year":"2016","unstructured":"Low, H. B. & Zhang, Y. Regulatory roles of MAPK phosphatases in cancer. Immune Netw. 16, 85\u201398 (2016).","journal-title":"Immune Netw."},{"key":"1087_CR43","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/onc.2015.300","volume":"35","author":"X Li","year":"2016","unstructured":"Li, X. et al. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK\/c-Jun\/AP-1 pathway. Oncogene 35, 2453\u20132464 (2016).","journal-title":"Oncogene"},{"key":"1087_CR44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1053\/j.gastro.2014.01.062","volume":"146","author":"Q Gao","year":"2014","unstructured":"Gao, Q. et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 146, 1397\u20131407 (2014).","journal-title":"Gastroenterology"},{"key":"1087_CR45","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/hep.28149","volume":"62","author":"LX Yang","year":"2015","unstructured":"Yang, L. X. et al. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial\u2013mesenchymal transition. Hepatology 62, 1804\u20131816 (2015).","journal-title":"Hepatology"},{"key":"1087_CR46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/00000478-200109000-00013","volume":"25","author":"T Seidal","year":"2001","unstructured":"Seidal, T., Balaton, A. J. & Battifora, H. Interpretation and quantification of immunostains. Am. J. Surg. Pathol. 25, 1204\u20131207 (2001).","journal-title":"Am. J. Surg. Pathol."},{"key":"1087_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8307","volume":"6","author":"A Balasubramani","year":"2015","unstructured":"Balasubramani, A. et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat. Commun. 6, 7307 (2015).","journal-title":"Nat. Commun."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1087-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:22:56Z","timestamp":1671538976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1087-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1087-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1036"}}